Form D · Biotechnology
RESVERLOGIX CORP.
Calgary, Alberta, A0 · CIK 0001372821
Offering snapshot reported Dec 1, 2011 · SEC filing
- Reported sold
- $1.84M Offering amount: $1.84M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 29, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 1, 2011 | Initial | $1,841,995 | No comparison | 1 | SEC filing |
| Jun 21, 2011 | Initial | $10,486,899 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-169463
Common Shares
Source: Form D, filed Dec 1, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| A. Brad Cann | Executive |
| F. Allan Gordon | Executive |
| Arthur J. Higgins | Director |
| Peter Johann | Director |
| Jan O. Johansson | Executive |
| Kenneth Lebioda | Executive |
| Donald J. Mc Caffrey | Director, Executive |
| Kelly Mc Neill | Director |
| Tina Rarick | Executive |
| Eldon R. Smith | Director |
| Gregory S. Wagner | Executive |
| Norman C.W. Wong | Executive |
| Peter Young | Executive |
| Kenneth J. Zuerblis | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Suite 202 279 Midpark Way S.E.
Calgary, Alberta, A0, T2X 1M2
Calgary, Alberta, A0, T2X 1M2